Position in GRFS
as of Mar 31, 2026
· filed Apr 29, 2026
Position Value
$101,140
-$118,164 QoQ
Shares Held
12,611
-46.2% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GRFS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026R Squared Ltd holds $3,992,693 across 8 Drug Manufacturers - General names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NVS |
Novartis AG
|
5,411 | $848,011 | |
| 2 | SNY |
Sanofi
|
17,447 | $744,289 | |
| 3 | LLY |
ELI LILLY & Co
|
560 | $671,680 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
3,544 | $447,748 | |
| 5 | AZN |
Astrazeneca PLC
|
1,987 | $376,774 | |
| 6 | NVO |
Novo Nordisk A S
|
7,495 | $359,310 | |
| 7 | GSK |
GSK plc
|
5,244 | $274,890 | |
| 8 | AMRN |
Amarin Corp Plc\Uk
|
16,938 | $269,991 |
All Filings in GRFS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $101,140 | 12,611 | Shares | Sole | 2026-04-29 | |
| 2025-12-31 | $219,304 | 23,455 | Shares | Sole | 2026-01-30 | |
| 2025-09-30 | $207,765 | 20,860 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $94,684 | 10,474 | Shares | Sole | 2025-07-31 | |
| 2024-12-31 | $27,974 | 3,760 | Shares | Sole | 2025-01-23 | |
| No filing history on record for this holder in this stock. | ||||||